{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:01:09Z","timestamp":1777982469662,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572875"],"award-info":[{"award-number":["81572875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH291"],"award-info":[{"award-number":["ZR2021MH291"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cultivating Fund of The First Affiliated Hospital of Shandong First Medical University","award":["QYPY2022NSFC0613"],"award-info":[{"award-number":["QYPY2022NSFC0613"]}]},{"name":"CSCO-MSD Cancer Research Foundation","award":["Y-MSD2020-0350"],"award-info":[{"award-number":["Y-MSD2020-0350"]}]},{"name":"CSCO-PILOT Cancer Research Foundation","award":["Y-2019AZMS-0440"],"award-info":[{"award-number":["Y-2019AZMS-0440"]}]},{"name":"Wu Jieping Medical Foundation for Clinical Scientific Research","award":["320.6750.2020-12-16"],"award-info":[{"award-number":["320.6750.2020-12-16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04287-7","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:11:05Z","timestamp":1769490665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Songlin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuekai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baocheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4287_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331:1565\u20131570. https:\/\/doi.org\/10.1126\/science.1203486","journal-title":"Science"},{"key":"4287_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"4287_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12885-025-13566-6","volume":"25","author":"X Han","year":"2025","unstructured":"Han X, Chen Y, Xie H et al (2025) Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors. BMC Cancer 25:139. https:\/\/doi.org\/10.1186\/s12885-025-13566-6","journal-title":"BMC Cancer"},{"key":"4287_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68:1181\u20131190. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.033","journal-title":"J Hepatol"},{"key":"4287_CR5","doi-asserted-by":"publisher","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","volume":"2","author":"E De Martin","year":"2020","unstructured":"De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D (2020) Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep 2:100170. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100170","journal-title":"JHEP Rep"},{"key":"4287_CR6","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"4287_CR7","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB et al (2021) Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4287_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J (2024) NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw 22(9):582\u2013592. https:\/\/doi.org\/10.6004\/jnccn.2024.0057","journal-title":"J Natl Compr Canc Netw"},{"key":"4287_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","volume":"10","author":"V Cheung","year":"2019","unstructured":"Cheung V, Gupta T, Payne M, Middleton MR, Collier JD, Simmons A, Klenerman P, Brain O, Cobbold JF (2019) Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol 10:364\u2013371. https:\/\/doi.org\/10.1136\/flgastro-2018-101146","journal-title":"Frontline Gastroenterol"},{"key":"4287_CR10","doi-asserted-by":"publisher","first-page":"1875639","DOI":"10.1080\/2162402X.2021.1875639","volume":"10","author":"JR Patrinely Jr","year":"2021","unstructured":"Patrinely JR Jr, McGuigan B, Chandra S et al (2021) A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 10:1875639. https:\/\/doi.org\/10.1080\/2162402X.2021.1875639","journal-title":"Oncoimmunology"},{"key":"4287_CR11","doi-asserted-by":"publisher","first-page":"e0525","DOI":"10.1097\/HC9.0000000000000525","volume":"8","author":"SY Hwang","year":"2024","unstructured":"Hwang SY, Hsieh P, Zhang W et al (2024) Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis. Hepatol Commun 8:e0525. https:\/\/doi.org\/10.1097\/HC9.0000000000000525","journal-title":"Hepatol Commun"},{"key":"4287_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/14782715221088911","volume":"52","author":"S McIlwaine","year":"2022","unstructured":"McIlwaine S, Cullen A, Stratton L, Oladipo B, Cash J, Carser J, Braniff C (2022) The use of tacrolimus in the management of checkpoint inhibitor immunotherapy-induced hepatitis. J R Coll Phys Edinb 52:20\u201323. https:\/\/doi.org\/10.1177\/14782715221088911","journal-title":"J R Coll Phys Edinb"},{"key":"4287_CR13","doi-asserted-by":"publisher","first-page":"e008074","DOI":"10.1136\/jitc-2023-008074","volume":"12","author":"E Burri","year":"2024","unstructured":"Burri E, Mangana J, Cheng PF, Schneider A, Weber A, Dummer R, Ramelyte E (2024) Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids. J Immunother Cancer 12:e008074. https:\/\/doi.org\/10.1136\/jitc-2023-008074","journal-title":"J Immunother Cancer"},{"key":"4287_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1177\/10781552221103548","volume":"29","author":"A Tew","year":"2023","unstructured":"Tew A, Khoja L, Pallan L, Steven N (2023) Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. J Oncol Pharm Pract 29:1163\u20131171. https:\/\/doi.org\/10.1177\/10781552221103548","journal-title":"J Oncol Pharm Pract"},{"key":"4287_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","volume":"67","author":"HM McGuire","year":"2018","unstructured":"McGuire HM, Shklovskaya E, Edwards J (2018) Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 67:563\u2013573. https:\/\/doi.org\/10.1007\/s00262-017-2107-7","journal-title":"Cancer Immunol Immunother"},{"key":"4287_CR16","doi-asserted-by":"publisher","first-page":"e001322","DOI":"10.1136\/jitc-2020-001322","volume":"8","author":"DC Ziogas","year":"2020","unstructured":"Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H (2020) When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 8:e001322. https:\/\/doi.org\/10.1136\/jitc-2020-001322","journal-title":"J Immunother Cancer"},{"key":"4287_CR17","doi-asserted-by":"publisher","first-page":"113313","DOI":"10.1016\/j.ejca.2023.113313","volume":"193","author":"E Alouani","year":"2023","unstructured":"Alouani E, Laparra A, Perret A et al (2023) Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. Eur J Cancer 193:113313. https:\/\/doi.org\/10.1016\/j.ejca.2023.113313","journal-title":"Eur J Cancer"},{"key":"4287_CR18","doi-asserted-by":"publisher","first-page":"1156746","DOI":"10.3389\/fimmu.2023.1156746","volume":"14","author":"M Zarrabi","year":"2023","unstructured":"Zarrabi M, Hamilton C, French SW, Federman N, Nowicki TS (2023) Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report. Front Immunol 14:1156746. https:\/\/doi.org\/10.3389\/fimmu.2023.1156746","journal-title":"Front Immunol"},{"key":"4287_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","volume":"79","author":"M Cunningham","year":"2024","unstructured":"Cunningham M, Gupta R, Butler M (2024) Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology 79:198\u2013212. https:\/\/doi.org\/10.1097\/HEP.0000000000000045","journal-title":"Hepatology"},{"key":"4287_CR20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","volume":"15","author":"M Biewenga","year":"2021","unstructured":"Biewenga M, van der Kooij MK, Wouters MWJM et al (2021) Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatol Int 15:510\u2013519. https:\/\/doi.org\/10.1007\/s12072-021-10151-4","journal-title":"Hepatol Int"},{"issue":"21","key":"4287_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/TCRM.S514868","volume":"25","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu L, Zhao M, Chen W, Chen Y, Zhao X (2025) The higher incidence of liver injury in HCC patients compared to other malignancies during immune-checkpoint inhibitor therapy is primarily due to tumor progression. Ther Clin Risk Manag 25(21):963\u2013974. https:\/\/doi.org\/10.2147\/TCRM.S514868","journal-title":"Ther Clin Risk Manag"},{"key":"4287_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/apt.18403","volume":"61","author":"YP Hung","year":"2025","unstructured":"Hung YP, Lee PC, Chang YH et al (2025) Hepatic events during immune checkpoint inhibitor treatment between liver and non-liver malignancies in hepatitis B endemic areas. Aliment Pharmacol Ther 61:501\u2013512. https:\/\/doi.org\/10.1111\/apt.18403","journal-title":"Aliment Pharmacol Ther"},{"key":"4287_CR23","doi-asserted-by":"publisher","first-page":"684110","DOI":"10.3389\/fonc.2021.684110","volume":"11","author":"V Nardone","year":"2021","unstructured":"Nardone V, Giannicola R, Bianco G et al (2021) Inflammatory markers and procalcitonin predict the outcome of metastatic non-small-cell-lung-cancer patients receiving PD-1\/PD-L1 immune-checkpoint blockade. Front Oncol 11:684110. https:\/\/doi.org\/10.3389\/fonc.2021.684110","journal-title":"Front Oncol"},{"key":"4287_CR24","doi-asserted-by":"publisher","first-page":"e006982","DOI":"10.1136\/jitc-2023-006982","volume":"11","author":"Y Li","year":"2023","unstructured":"Li Y, Jia X, Zhang Y, Du Y, Chang Y, Shen Y, Mao Z, Liu M, Sun H, Guo H (2023) Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis. J Immunother Cancer 11:e006982. https:\/\/doi.org\/10.1136\/jitc-2023-006982","journal-title":"J Immunother Cancer"},{"key":"4287_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","volume":"42","author":"JH Kang","year":"2021","unstructured":"Kang JH, Bluestone JA, Young A (2021) Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines. Trends Immunol 42:293\u2013311. https:\/\/doi.org\/10.1016\/j.it.2021.02.006","journal-title":"Trends Immunol"},{"key":"4287_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","volume":"24","author":"A Pavan","year":"2019","unstructured":"Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L (2019) Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist 24:1128\u20131136. https:\/\/doi.org\/10.1634\/theoncologist.2018-0563","journal-title":"Oncologist"},{"key":"4287_CR27","doi-asserted-by":"publisher","first-page":"1480183","DOI":"10.3389\/fimmu.2024.1480183","volume":"15","author":"SJ Farooqi","year":"2024","unstructured":"Farooqi SJ, Zhao Z, \u00d6jlert \u00c5K, Thunold S, Juul HV, Bjaan\u00e6s MM, Horndalsveen H, Nymoen HMG, Helland \u00c5, Haakensen VD (2024) Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma. Front Immunol 15:1480183. https:\/\/doi.org\/10.3389\/fimmu.2024.1480183","journal-title":"Front Immunol"},{"key":"4287_CR28","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","volume":"145","author":"AR Abolhassani","year":"2019","unstructured":"Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L (2019) C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol 145:2625\u20132631. https:\/\/doi.org\/10.1007\/s00432-019-03002-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"4287_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","volume":"4","author":"NG Nu\u00f1ez","year":"2023","unstructured":"Nu\u00f1ez NG, Berner F, Friebel E et al (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med 4:113-129.e7. https:\/\/doi.org\/10.1016\/j.medj.2022.12.007","journal-title":"Med"},{"key":"4287_CR30","doi-asserted-by":"publisher","first-page":"e011636","DOI":"10.1136\/jitc-2025-011636","volume":"13","author":"SI Shin","year":"2025","unstructured":"Shin SI, Sun P, Lee JE, Chung C, Kang YE, Kang DH, Park J (2025) Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC. J Immunother Cancer 13:e011636. https:\/\/doi.org\/10.1136\/jitc-2025-011636","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4287_CR31","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","volume":"25","author":"SY Lim","year":"2019","unstructured":"Lim SY, Lee JH, Gide TN et al (2019) Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res 25(5):1557\u20131563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2795","journal-title":"Clin Cancer Res"},{"key":"4287_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/s0161-5890(02)00210-9","volume":"39","author":"S Diehl","year":"2002","unstructured":"Diehl S, Rinc\u00f3n M (2002) The two faces of IL-6 on Th1\/Th2 differentiation. Mol Immunol 39:531\u2013536. https:\/\/doi.org\/10.1016\/s0161-5890(02)00210-9","journal-title":"Mol Immunol"},{"key":"4287_CR33","doi-asserted-by":"publisher","first-page":"e176567","DOI":"10.1172\/JCI176567","volume":"134","author":"CJ Kao","year":"2024","unstructured":"Kao CJ, Charmsaz S, Alden SL et al (2024) Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures. J Clin Invest 134:e176567. https:\/\/doi.org\/10.1172\/JCI176567","journal-title":"J Clin Invest"},{"key":"4287_CR34","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00432-021-03750-z","volume":"2022","author":"B Kowalski","year":"2022","unstructured":"Kowalski B, Valaperti A, Bezel P, Steiner UC, Scholtze D, Wieser S, Vonow-Eisenring M, Widmer A, Kohler M, Franzen D (2022) Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study. J Cancer Res Clin Oncol 2022:1711\u20131720. https:\/\/doi.org\/10.1007\/s00432-021-03750-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"4287_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","volume":"86","author":"R Tanaka","year":"2017","unstructured":"Tanaka R, Okiyama N, Okune M et al (2017) Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity. J Dermatol Sci 86:71\u201373. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.12.019","journal-title":"J Dermatol Sci"},{"key":"4287_CR36","doi-asserted-by":"publisher","first-page":"e0260254","DOI":"10.1371\/journal.pone.0260254","volume":"16","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Fujita Y, Asano T et al (2021) Association between inflammatory cytokines and immune-checkpoint molecule in rheumatoid arthritis. PLoS ONE 16:e0260254. https:\/\/doi.org\/10.1371\/journal.pone.0260254","journal-title":"PLoS ONE"},{"issue":"46","key":"4287_CR37","doi-asserted-by":"publisher","first-page":"e31761","DOI":"10.1097\/MD.0000000000031761","volume":"101","author":"X Zhang","year":"2022","unstructured":"Zhang X, Lu X, Yu Y, Tan K, Cui H (2022) Changes of IL-6 and IFN-\u03b3 before and after the adverse events related to immune checkpoint inhibitors: a retrospective study. Medicine (Baltimore) 101(46):e31761. https:\/\/doi.org\/10.1097\/MD.0000000000031761","journal-title":"Medicine (Baltimore)"},{"key":"4287_CR38","doi-asserted-by":"publisher","first-page":"906824","DOI":"10.3389\/fonc.2022.906824","volume":"12","author":"Y Yu","year":"2022","unstructured":"Yu Y, Wang S, Su N et al (2022) Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer. Front Oncol 12:906824. https:\/\/doi.org\/10.3389\/fonc.2022.906824","journal-title":"Front Oncol"},{"key":"4287_CR39","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","volume":"147","author":"B Husain","year":"2021","unstructured":"Husain B, Kirchberger MC, Erdmann M, Sch\u00fcpferling S, Abolhassani AR, Fr\u00f6hlich W, Berking C, Heinzerling L (2021) Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol 147:1623\u20131630. https:\/\/doi.org\/10.1007\/s00432-021-03550-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"4287_CR40","doi-asserted-by":"publisher","first-page":"1553882","DOI":"10.3389\/fimmu.2025.1553882","volume":"16","author":"H Ma","year":"2025","unstructured":"Ma H, Zhang S, Jiao P, Ding H, Wang F, Zhao Y, Wu J, Guo Z (2025) Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment. Front Immunol 16:1553882. https:\/\/doi.org\/10.3389\/fimmu.2025.1553882","journal-title":"Front Immunol"},{"key":"4287_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41419-024-06535-7","volume":"15","author":"L Shojaie","year":"2024","unstructured":"Shojaie L, Bogdanov JM, Alavifard H et al (2024) Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis 15:140. https:\/\/doi.org\/10.1038\/s41419-024-06535-7","journal-title":"Cell Death Dis"},{"key":"4287_CR42","doi-asserted-by":"publisher","unstructured":"Ito T, Yamamoto T, Nishida K et al (2025) Fever following treatment with Atezolizumab plus Bevacizumab predicts liver injury in patients with unresectable hepatocellular carcinoma: a prospective observational analysis. Liver Cancer. https:\/\/doi.org\/10.1159\/000546967","DOI":"10.1159\/000546967"},{"key":"4287_CR43","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","volume":"149","author":"A Miah","year":"2023","unstructured":"Miah A, Tinoco G, Zhao S et al (2023) Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol 149:2235\u20132242. https:\/\/doi.org\/10.1007\/s00432-022-04340-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"4287_CR44","doi-asserted-by":"publisher","first-page":"2543510","DOI":"10.1080\/2162402X.2025.2543510","volume":"14","author":"H Al Remawi","year":"2025","unstructured":"Al Remawi H, Lind\u00e9n M, Zhao Z, Pandita A, Rudin A, Ny L, Bjursten S, Levin M (2025) Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab. Oncoimmunology 14:2543510. https:\/\/doi.org\/10.1080\/2162402X.2025.2543510","journal-title":"Oncoimmunology"},{"key":"4287_CR45","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/hepr.13878","volume":"53","author":"S Kaneko","year":"2023","unstructured":"Kaneko S, Asahina Y, Nakagawa M et al (2023) Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatol Res 53:450\u2013459. https:\/\/doi.org\/10.1111\/hepr.13878","journal-title":"Hepatol Res"},{"key":"4287_CR46","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s12072-025-10825-3","volume":"19","author":"K Matsumoto","year":"2025","unstructured":"Matsumoto K, Kanda T, Wakatsuki J et al (2025) Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors. Hepatol Int 19:1221\u20131230. https:\/\/doi.org\/10.1007\/s12072-025-10825-3","journal-title":"Hepatol Int"},{"key":"4287_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00432-021-03870-6","volume":"148","author":"MT Purde","year":"2022","unstructured":"Purde MT, Niederer R, Wagner NB et al (2022) Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 148:647\u2013656. https:\/\/doi.org\/10.1007\/s00432-021-03870-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"4287_CR48","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2147\/JHC.S464105","volume":"11","author":"CH Lin","year":"2024","unstructured":"Lin CH, Kuo YC, Kuo HC, Wang CT, Lin SM, Lee AC, Yu MC, Lee WC, Chen CC, Hsieh JC (2024) Absence of survival impact from hepatitis during immunotherapy in 193 patients with advanced hepatocellular carcinoma - an observational study from Taiwan. J Hepatocell Carcinoma 11:1875\u20131890. https:\/\/doi.org\/10.2147\/JHC.S464105","journal-title":"J Hepatocell Carcinoma"},{"key":"4287_CR49","doi-asserted-by":"publisher","first-page":"984940","DOI":"10.3389\/fonc.2022.984940","volume":"12","author":"LA Swanson","year":"2022","unstructured":"Swanson LA, Kassab I, Tsung I, Schneider BJ, Fontana RJ (2022) Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis. Front Oncol 12:984940. https:\/\/doi.org\/10.3389\/fonc.2022.984940","journal-title":"Front Oncol"},{"key":"4287_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/07357907.2021.1994586","volume":"40","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Ito T, Hase T et al (2022) Immune-related liver injury is a poor prognostic factor in patients with nonsmall cell lung cancer treated with immune checkpoint inhibitors. Cancer Invest 40:189\u2013198. https:\/\/doi.org\/10.1080\/07357907.2021.1994586","journal-title":"Cancer Invest"},{"key":"4287_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/JHC.S431191","volume":"11","author":"J Shen","year":"2024","unstructured":"Shen J, Wang X, Yang G, Li L, Fu J, Xu W, Zhang Q, Pan X (2024) Liver injury and its impact on prognosis in patients with HBV-related hepatocellular carcinoma undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors. J Hepatocell Carcinoma 11:207\u2013217. https:\/\/doi.org\/10.2147\/JHC.S431191","journal-title":"J Hepatocell Carcinoma"},{"key":"4287_CR52","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"4287_CR53","doi-asserted-by":"publisher","first-page":"e24093","DOI":"10.1200\/JCO.2025.43.16_suppl.e24093","volume":"43","author":"Z Hong","year":"2025","unstructured":"Hong Z, Guan Y, Xie H, Chen Y, Zhang Y, Zhang B, Wang J (2025) Delayed immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. J Clin Oncol 43:e24093\u2013e24093. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e24093","journal-title":"J Clin Oncol"},{"key":"4287_CR54","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s10238-025-01721-z","volume":"25","author":"H Hu","year":"2025","unstructured":"Hu H, Shen X, Chen J (2025) Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury. Clin Exp Med 25:288. https:\/\/doi.org\/10.1007\/s10238-025-01721-z","journal-title":"Clin Exp Med"},{"key":"4287_CR55","doi-asserted-by":"publisher","first-page":"1385794","DOI":"10.3389\/fonc.2025.1385794","volume":"15","author":"C Jiang","year":"2025","unstructured":"Jiang C, Guo S (2025) Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report. Front Oncol 15:1385794. https:\/\/doi.org\/10.3389\/fonc.2025.1385794","journal-title":"Front Oncol"},{"key":"4287_CR56","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s12328-023-01832-8","volume":"16","author":"K Sato","year":"2023","unstructured":"Sato K, Inoue J, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Ouchi K, Masamune A (2023) Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil. Clin J Gastroenterol 16:720\u2013725. https:\/\/doi.org\/10.1007\/s12328-023-01832-8","journal-title":"Clin J Gastroenterol"},{"key":"4287_CR57","doi-asserted-by":"publisher","first-page":"e25774","DOI":"10.1097\/MD.0000000000025774","volume":"100","author":"Y Hirasawa","year":"2021","unstructured":"Hirasawa Y, Yoshimura K, Matsui H et al (2021) A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore) 100:e25774. https:\/\/doi.org\/10.1097\/MD.0000000000025774","journal-title":"Medicine (Baltimore)"},{"key":"4287_CR58","doi-asserted-by":"publisher","first-page":"e20221333","DOI":"10.1084\/jem.20221333","volume":"220","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Medik YB, Patel B et al (2023) Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 220:e20221333. https:\/\/doi.org\/10.1084\/jem.20221333","journal-title":"J Exp Med"},{"key":"4287_CR59","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.annonc.2024.12.004","volume":"36","author":"D Daoudlarian","year":"2024","unstructured":"Daoudlarian D, Segot A, Latifyan S et al (2024) Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy. Ann Oncol 36:444\u2013459. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.004","journal-title":"Ann Oncol"},{"key":"4287_CR60","doi-asserted-by":"publisher","first-page":"e006814","DOI":"10.1136\/jitc-2023-006814","volume":"11","author":"F Fa\u2019ak","year":"2023","unstructured":"Fa\u2019ak F, Buni M, Falohun A et al (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11:e006814. https:\/\/doi.org\/10.1136\/jitc-2023-006814","journal-title":"J Immunother Cancer"},{"key":"4287_CR61","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, Cherukuri S, Parent T, Hardin J, Walker P (2019) Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 25:551\u2013557. https:\/\/doi.org\/10.1177\/1078155217745144","journal-title":"J Oncol Pharm Pract"},{"key":"4287_CR62","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2217\/imt-2023-0085","volume":"15","author":"SB Ali","year":"2023","unstructured":"Ali SB, Vembar P, Sukumaran S, Gunawardane D, Hughes T, Smith A (2023) Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature. Immunotherapy 15:1125\u20131132. https:\/\/doi.org\/10.2217\/imt-2023-0085","journal-title":"Immunotherapy"},{"key":"4287_CR63","doi-asserted-by":"publisher","first-page":"e01162","DOI":"10.14309\/crj.0000000000001162","volume":"10","author":"L Lyles","year":"2023","unstructured":"Lyles L, Farmer R, Abougergi M (2023) A potential new use for Tocilizumab: refractory checkpoint inhibitor hepatitis. ACG Case Rep J 10:e01162. https:\/\/doi.org\/10.14309\/crj.0000000000001162","journal-title":"ACG Case Rep J"},{"key":"4287_CR64","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","volume":"16","author":"L Moi","year":"2021","unstructured":"Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M (2021) Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. J Thorac Oncol 16:318\u2013326. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.007","journal-title":"J Thorac Oncol"},{"key":"4287_CR65","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","volume":"157","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV (2021) Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer 157:214\u2013224. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.031","journal-title":"Eur J Cancer"},{"key":"4287_CR66","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.21037\/tlcr-2025-341","volume":"14","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Wang H (2025) Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report. Transl Lung Cancer Res 14:2875\u20132879. https:\/\/doi.org\/10.21037\/tlcr-2025-341","journal-title":"Transl Lung Cancer Res"},{"key":"4287_CR67","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3332\/ecancer.2023.1644","volume":"17","author":"C Nagpal","year":"2023","unstructured":"Nagpal C, Rastogi S, Shamim SA, Prakash S (2023) Re-challenge of immune checkpoint inhibitor pembrolizumab with concurrent tocilizumab after prior grade 3 pneumonitis. Ecancermedicalscience 17:1644. https:\/\/doi.org\/10.3332\/ecancer.2023.1644","journal-title":"Ecancermedicalscience"},{"key":"4287_CR68","doi-asserted-by":"publisher","first-page":"e013038","DOI":"10.1136\/jitc-2025-013038","volume":"13","author":"KN Oliva","year":"2025","unstructured":"Oliva KN, Arnold L, Heinzerling L et al (2025) Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis. J Immunother Cancer 13:e013038. https:\/\/doi.org\/10.1136\/jitc-2025-013038","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04287-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:11:08Z","timestamp":1769490668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04287-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4287"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04287-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8088849\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Research Ethics Committee of the First Affiliated Hospital of Shandong First Medical University (NO: YXLL-KY-2022\u2013059).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Owing to the retrospective design of the study, the Research Ethics Committee of the First Affiliated Hospital of Shandong First Medical University granted a waiver of the requirement for informed consent. We confirmed that all methods were performed in accordance with the relevant guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"43"}}